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Abstract
Hydralazine was one of the first orally active antihypertensive drugs developed. Currently, it is used principally to treat
pregnancy-associated hypertension. Hydralazine causes two types of side effects. The first type is an extension of the
pharmacologic effect of the drug and includes headache, nausea, flushing, hypotension, palpitation, tachycardia, dizziness,
and salt retention. The second type of side effects is caused by immunologic reactions, of which the drug-induced lupus-
like syndrome is the most common, and provides clues to underscoring hydralazine's DNA demethylating property in
connection with studies demonstrating the participation of DNA methylation disorders in immune diseases.
Abnormalities in DNA methylation have long been associated with cancer. Despite the fact that malignant tumors show
global DNA hypomethylation, regional hypermethylation as a means to silence tumor suppressor gene expression has
attracted the greatest attention. Reversibility of methylation-induced gene silencing by pharmacologic means, which in
turns leads to antitumor effects in experimental and clinical scenarios, has directed efforts toward developing clinically
useful demethylating agents. Among these, the most widely used comprise the nucleosides 5-azacytidine and 2'deoxy-5-
azacytidine; however, these agents, like current cytotoxic chemotherapy, causes myelosuppression among other side
effects that could limit exploitation of their demethylating properties. Among non-nucleoside DNA demethylating drugs
currently under development, the oral drug hydralazine possess the ability to reactivate tumor suppressor gene
expression, which is silenced by promoter hypermethylation in vitro and in vivo. Decades of extensive hydralazine use for
hypertensive disorders that demonstrated hydralazine's clinical safety and tolerability supported its testing in a phase I
trial in patients with cancer, confirming its DNA demethylating activity. Hydralazine is currently being evaluated, along
with histone deacetylase inhibitors either alone or as adjuncts to chemotherapy and radiation, for hematologic and solid
tumors in phase II studies.
Review
Hydralazine as an antihypertensive
Hydralazine, a potent arterial vasodilator that reduces
peripheral resistance directly by relaxing the smooth mus-
cle cell layer in arterial vessels, has long been used for
management of hypertensive disorders and heart failure
[1,2]; nonetheless, its current use is limited nearly to
hypertensive disorders during pregnancy [3,4]. Despite
numerous studies with the drug, its mechanism of action
has remained unknown but it is suggested that hydrala-
zine may function by either modulating the effect of
purine-like compounds released from sympathetic nerve
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endings, and/or by producing an altered Ca2+ balance in
vascular smooth muscle cells [5-7]. The majority of its
effects are confined to the cardiovascular system. Decrease
in blood pressure after hydralazine administration is asso-
ciated with a selective decrease in vascular resistance in
coronary, cerebral, and renal circulation, with a lesser
effect in skin and muscle. Hydralazine lowers peripheral
vascular resistance equally in supine and upright posi-
tions; it also lowers pulmonary vascular resistance and
increases cardiac output causing mild pulmonary hyper-
tension. [1,2].
Hydralazine is well absorbed through the gastrointestinal
tract, but systemic bioavailability is low. Because the
acetylated compound is inactive, the dose necessary to
produce a systemic effect is higher in fast acetylators. N-
acetylation of hydralazine occurs in bowel and/or liver.
Hydralazine's half-life is 1 h and systemic clearance of the
drug is approximately 50 mL/kg/min. Hydralazine rapidly
combines with circulating α keto-acid to form hydra-
zones, and the major metabolite recovered from the
plasma is hydralazine piruvic acid hydrazone. This metab-
olite possesses a longer half-life than hydralazine but does
not appear to be very active. Systemic metabolism is
dependent on hydroxylation followed by conjugation
with glucoronic acid in liver, which is not dependent on
acetylation rate; therefore, half-life does not differ to a
great degree between slow and fast acetylators [8].
Hydralazine peak concentration in plasma and peak
hypotensive effect of the drug occurs within 30–120 min
of ingestion. Although its half-life in plasma is approxi-
mately 1 h, duration of the hypotensive effect can last as
long as 12 h; there is no clear explanation for this discrep-
ancy. The antihypertensive effect of hydralazine has no
clear dose-response effects. The dose varies from 10 mg
four times a day to 50 mg four times daily. After stabiliza-
tion with multiple daily doses, a twice-daily dose regimen
can be effective. Slow acetylators require a lower dose. For
heart failure, recommended doses are higher (up to 800
mg daily or more); as a rule, 10–100 mg four times a day
can be effective [9].
Two types of side effects occur after hydralazine use. The
first type, an extension of hydralazine's pharmacologic
effect, includes headache, nausea, flushing, hypotension,
palpitation, tachycardia, dizziness, and angina pectoris;
hydralazine can produce salt retention with congestive
heart failure development. The second type of side effect
is caused by immunologic reactions, of which the drug-
induced lupus-like syndrome is the most common [8,9].
Cancer epigenetics
Epigenetics can be defined as the study of mitotically and/
or meiotically heritable changes in gene function that can
not be explained by changes in DNA sequence. There are
two epigenetic systems that affect animal development
and fulfill the heritability criterion: DNA methylation,
and the polycomb-trithorax group (Pc-G/trx) protein
complexes; nevertheless, post-transductional histone
modification possesses some attributes of an epigenetic
process and as such are studied within this field [10]. Epi-
genetics is a well-established phenomenon that plays a
major role in a diversity of biological processes such as
embryonic development, cancer biology, and immune
system response, among many others. The two most
widely studied epigenetic changes are DNA methylation
and histone acetylation; however, the picture is much
more complicated than this, with new players coming
into the scenario; these include, among others, the RNA
interference phenomenon, proven to be implicated in
transcriptional silencing through small duplex RNA mol-
ecules that recruit silencing complexes to the chromatin,
and the BORIS (Brother of the Regulator of Imprinted
Sites)/CTCF gene family, which is involved in epigenetic
reprogramming events [11,12].
DNA methylation
DNA methylation is a covalent chemical modification
that mainly occurs at the cytosine ring, resulting in the
addition of a methylCH3 group at the carbon 5 position.
Because DNA is made up of four bases, 16 possible dinu-
cleotide combinations can occur; hence, the CpG dinucle-
otide should have a frequency of 6%. Nonetheless, actual
presence is only 5–10% of its predicted frequency. The
human genome is not uniformly methylated and contains
regions of unmethylated interspersed with methylated
segment regions. In contrast to the remainder of the
genome, smaller regions of DNA – denominated CpG
islands, ranging from 0.5–5 kb, and occurring on average
every 100 kb – possess distinctive properties. These
regions are unmethylated, GC-rich (60–70%), have a
ratio of CpG:GpC of at least 0.6, and thus show no sup-
pression of dinucleotide CpG frequency. Approximately
one half of all genes in humans have CpG islands, these
present in both housekeeping genes and in genes with tis-
sue-specific patterns of expression [13,14].
At least three functional DNA methyltransferases (DNMT)
have been identified; the most abundant is DNMT1, or
maintenance DNMT. This methyltransferase enzyme cop-
ies pre-existing methylation patterns onto the new DNA
strand during DNA replication to ensure clonal transmis-
sion of lineage-specific DNA methylation patterns in a
mammalian genome during replication. Thus, DNMT1 is
targeted to replication foci, interacts with proliferating cell
nuclear antigen, and favors methylating the hemimethyl-
ated form of CpG sites. It has been demonstrated that
DNMT1 methylates hemimethylated DNA with high
processivity and a fidelity of >95% on one strand of dou-
ble-stranded DNA during a single processive run; never-Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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theless, DNMT1 methylates unmethylated DNA with
much less processivity, suggesting that these inherent
enzymatic properties of Dnmt1 play an essential role in
the faithful and efficient maintenance of methylation pat-
terns in the mammalian genome [15,16].
Other known functional methyltransferases include
DNMT3a and DNMT3b, which are responsible for de novo
methylation during embryogenesis; thus, these have been
classified as de novo methyltransferases [17]. These
enzymes are mainly responsible for introducing cytosine
methylation at previously unmethylated CpG sites by at
least three possible means: first, DNMT3 enzymes them-
selves might recognize DNA or chromatin via specific
domains; second, DNMT3a and DNMT3b might be
recruited through protein-protein interactions with tran-
scriptional repressors or other factors, and third, the RNA-
mediated interference (RNAi) system might target de novo
methylation to specific DNA sequences [18].
In addition to DNMTs, the machinery of methylation
includes demethylases, methylation centers that trigger
DNA methylation, and methylation protection centers
[19]. The effect of DNA methylation on gene transcription
can be observed only within the context of chromatin
remodeling players. DNA methylation can interfere
directly with transcriptional factor binding, thus inhibit-
ing replication [20], in addition to the ability of DNA
methyltransferases DNMT1, DNMT3a, and DNMT3b to
repress transcription in a methylation-independent man-
ner [21]. Methyl-CpG-binding proteins, which can recog-
nize methylated DNA, have been shown to associate with
large protein complexes containing HDACs and chroma-
tin-remodeling activities. It has also been suggested that
DNA methylation could produce gene silencing by
methyl-binding domain proteins that recruit histone
methyltransferases, which methylate lysine 9 in histone
H3 and subsequently repress gene transcription [22]. As a
result, histones are deacetylated and gene transcription
repressed.
Histones and post-translational modifications
How double-strand DNA is packaged into the dynamic
structure of chromatin is crucial for the transcriptional
control process by regulating transcription factor accessi-
bility to DNA regulatory sequences. Chromatin is consti-
tuted of nucleosomes, which are comprised of 146 base
pairs of DNA wrapped around a core of two copies each of
histones H2A, H2B, H3, and H4. The N-terminal tails of
histones, which undergo post-translational modifications
such as acetylation, methylation, ubiquitination, phos-
phorylation, and sumoylation, protrude from their origi-
nating nucleosome and may contact adjacent
nucleosomes as well as chromatin-associated proteins.
These interactions are responsible, at least in part, for reg-
ulating chromatin structure [23]. The most widely studied
modification is acetylation, which plays diverse roles in
nucleosome regulation. Lysine acetylation, for example,
may decrease histone-DNA interaction and promote
accessibility of DNA for transcription activation. Moreo-
ver, acetylation specifically can also regulate DNA replica-
tion, histone deposition, and DNA repair by mechanisms
of recruiting proteins that have an acetyl-lysine binding
module, the bromodomain, a 100-amino-acid conserved
sequence found in many chromatin-associated proteins.
Thus, bromodomains in histone acetyltransferases and
nucleosome remodeling complexes orchestrate the suc-
cession of chromatin regulators at a target site [24,25].
Overall, lysine acetylation results in chromatin decom-
pactation, greater access of DNA to transcription factors,
and the presence of a transcriptionally active genomic
locus. This post-translational modification depends on
the net local balance between histone acetyl transferase
(HAT) and histone deacetylase (HDAC) activities. In gen-
eral, hyperacetylation is found in more decondensed
euchromatin, whereas hypoacetylation is characteristic of
more condensed heterochromatin [26,27].
Epigenetic alterations and cancer
Abnormalities in DNA methylation have long been asso-
ciated with cancer. Both hypo- and hypermethylation play
prominent roles in carcinogenesis, and their contribution
exhibits poorly defined boundaries. It has been known for
some time that both alterations co-exist in cancer cells:
malignant tumors exhibit global hypomethylation and
regional hypermethylation. Whether one must precede
the other or whether both should begin at the same time
remains to be elucidated. In terms of carcinogenesis, ini-
tial observations were conducted on hypomethylation [28
29]; later, discovery of regional hypermethylation as a
means to silence tumor suppressor gene expression
gained the most attention [30].
Silencing of tumor suppressor genes
Observations that tumor suppressor gene function can be
disrupted not only through structural changes (mutation
and deletion) but also by lack of promoter hypermethyla-
tion-associated expression positioned tumor suppressor
gene epigenetic silencing as a well-established oncogenic
process [31]. The first suppressor gene known to be hyper-
methylated and silenced was Rb [32]. This finding was
soon followed by multiple publications describing similar
findings for a variety of tumor suppressor genes, among
them p16, MLH1, VHL, and E-cadherin [33]. Whether gene
promoter hypermetylation is the cause or consequence of
tumor suppressor gene silencing remains a matter of con-
troversy; nevertheless, these views are not mutually exclu-
sive. That DNA methylation is causal has been shown by
the ability of diverse pharmacologic compounds and
molecular techniques to reactivate gene expression uponJournal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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inhibition of DNA methylation in cancer cells [34]. On
the other hand, other findings suggest that hypermethyla-
tion-induced gene silencing could be associated with
changes that determine gene expression, such as chroma-
tin modification, so that methylation aids in maintaining
the gene's silenced status. Strong support for the second
view has derived from experiments showing that histone
H3 lysine 9 methylation – that is, chromatin modification
– occurred along with p16 re-silencing in absence of DNA
methylation in cells in which p16 had previously been
activated by DNA methyltransferase knock-out [35], and
by data demonstrating p16 silencing in mammary epithe-
lial cells that had escaped senescence and demethylated
the promoter [36].
Silencing of genes involved in tumor-host interaction
Although cancer cells are less immunogenic than patho-
gens, the immune system is clearly capable of recognizing
and eliminating tumor cells. However, tumors frequently
interfere with immune response development and func-
tion through several mechanisms such as loss of antigen
processing and presentation, the Fas counterattacking sys-
tem, escaping from death receptor signaling, engaging in
inhibition-blocking activation, suppression of antitumor
responses by regulatory T cells, and tumor-induced
immune suppression [37]. Current research demonstrates
that epigenetic defects are involved in at least some mech-
anisms that preclude mounting a successful host-antitu-
mor response, including the HLA system, tumor-
associated antigens, and accessory/co-stimulatory mole-
cules.
Among tumor-associated antigens, testis-associated genes
(CTA) are a sub-group of tumor antigens with restricted
expression in testis and malignancies; CTA include the
MAGE, NYESO, and SSX gene families and the GAGE/
PAGE/XAGE superfamilies [38]. Distinct CTA can encode
for different antigenic peptides that are presented to the
immune system in association with various human leuko-
cyte antigens (HLA), HLA class I or HLA class II allospecif-
icities, eliciting both cytotoxic T lymphocytes (CTL) and
humoral immune responses. De Smet et al., first showed
a link between genomic DNA hypomethylation and
MAGE-1  gene expression [39], and subsequent studies
demonstrated direct correlation between demethylation
of CpG at the promoter of several cancer testis antigen
coding genes with their expression [40-43]. Surprisingly,
5-aza-2'-deoxycytidine demethylation treatment led to
induction of MAGE-, GAGE-, PAGE-, and XAGE-type
genes in tumor cells but not in normal cells [44].
Presentation of antigens within the context of HLA mole-
cules is crucial both during T-cell priming and the effector
phase of an adaptive immune response. Alterations in
antigen processing and presentation are commonly
observed in malignancies. In tumors, the antigen presen-
Table 1: Agents targeting DNA methylation and histone deacetylase in preclinical and clinical development
DNA methylation inhibitors
deoxycytidine analogs:
5-azacytidine, 5-aza-2-deoxycytidine, 1-β-D-arabinofuranosil 5-azacytosine, dihydro- 5-azacytidine
nucleic acid-based:
MG98 antisense oligonucleotide
cytidine deaminase analogs:
zebularine
non-nucleoside analogs:
(-)-epigallocatechin-3-gallate, procaine, procainamide, hydralazine, RG108, psammaplins
Histone deacetylase inhibitors
Small molecular weight carboxilates:
sodium butyrate, valproic acid, sodium phenylbutyrate and pivaloyloxymethyl butyrate
Hydroxamic acids:
SAHA, trichostatin A, SBHA
Benzamides:
CI-994, MS-275
Epoxyketones:
trapoxin B, 2-amino-8-oxo-9,10-epoxydecanoic acid
Cyclic peptides:
apicidin, depsipeptide
Hybrid molecules:
CHAP 31, CHAP50
Miscellaneous:
Cyclostellettamines, Carbamazepine
Adapted from reference 106.Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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tation pathway is commonly disrupted as a consequence
of the mutations and/or deletions of one or several genes
encoding components of the antigen-processing machin-
ery, including proteasomal subunits and transporters pep-
tides; thus, complete HLA loss is a common event in
several murine and human tumors [45]. As for CTA, DNA
methylation participates in regulation of the expression of
the three classes of human leukocyte antigen class I anti-
gens: HLA-A; HLA-B, and HLA-C, which are CpG-rich at
their gene promoters. Nie et al. showed down-regulation
of HLA class I antigens in esophageal carcinoma as a com-
mon mechanism for transcriptional inactivation caused
primarily by DNA hypermethylation [46], as well as in
melanoma, where 5-aza-2'-deoxycytidine significantly
enhances the constitutive expression of HLA class I anti-
gens, of HLA-A1 and -A2 alleles, and of the co-stimulatory
molecule, intercellular adhesion molecule-1, and lym-
phocyte function-associated antigen-3 [47]. Further, it
was shown that 5-aza-2'-deoxycytidine leads to re-expres-
sion of HLA class I antigens and restoration of antigen-
specific CTL response in melanoma cells [48]; likewise, it
has been shown that methylation-induced silencing of the
class II transactivator (CIITA) leads to lack of HLA-DR
induction in hematopoietic tumor cells and solid tumors
such as gastric and colorectal carcinomas [49,50].
Current epigenetic therapy agents
Reactivation of tumor suppressor genes silenced by an
epigenetic mechanism such as gene promoter methyla-
tion is a very attractive molecular target for cancer therapy.
There are several demethylating agents currently being
evaluated in pre-clinical and clinical studies (Table 1). The
classical demethylating agents comprise the analogs of
deoxycytidine, including 5-azacytidine, 5-aza-2-deoxycy-
tidine, 1-β-D-arabinofuranosil-5-azacytosine, and dihy-
dro-5-azacytidine. 5-azacytidine and its analog 5-aza-2-
deoxycytidine are the most frequently studied and were
developed over 30 years ago as classical cytotoxic agents,
but were subsequently discovered to be effective DNA
methylation inhibitors [51]. These were tested as such in
several phase II studies against solid tumors, demonstrat-
ing very modest activity [52]. Contrariwise, their anti-
leukemic activity was very promising, and both are being
revived due to their demonstrated inhibitory activity upon
DNA methylation and gene-reactivating function.
Currently, 5-azacytidine is Federal Drug Administration
(FDA)-approved for use against myelodysplastic syn-
drome, and 5-aza-2-deoxycytidine is also being tested in
myelodysplastic syndrome and in a variety of solid
tumors due to its DNA demethylating properties [53]. In
particular, 5-aza-2-deoxycytidine when infused for 10
days proved to be well-tolerated and induced responses in
65% of 50 patients with acute myelogenous leukemia,
myelodysplasia, chronic myelogenous leukemia, and
acute lymphocytic leukemia [54]. Despite poor activity
against solid tumors of these nucleoside analogs, it is
remarkable that proof of the concept concerning the abil-
ity of DNA methylation compound inhibitors to demeth-
ylate and reactivate tumor suppresor gene expression has
been shown in solid tumors [55]. Whether or not the reac-
tivating effect can translate into a clinical response on its
own or in combination with classical cytotoxic therapies
remains to be demonstrated.
As a second category of demethylating agents, there is the
antisense oligonucleotide MG98 against the 3' untrans-
lated region of DNMT1 mRNA that codes for the enzyme
DNA methyltransferase 1, which is responsible for DNA
methylation maintenance [56]. This agent has shown an
ability to inhibit DNMT1 gene expression without affect-
ing other DNMTs and to cause demethylation with p16 re-
expression in bladder and colon cancer cell lines, as well
as to produce tumor growth inhibition in nude mice bear-
ing human lung and colon xenografts [57]. MG98 has
been evaluated in a phase I trial in patients with advanced
or refractory solid tumors and has demonstrated its toler-
ability, despite the fact that dose-limiting toxicities of
transaminitis, thrombocytopenia, and fatigue prohibited
higher doses. MG98's molecular efficacy was demon-
strated by producing a DNMT mRNA level decrease in the
peripheral blood cells in six of 10 patients [58].
The fact that deoxycytidine analogs, like current cytotoxic
agents, are not only carcinogenic but also exhibit neutro-
penia as their dose-limiting toxicity even when used at
doses required for demethylation [59] has renewed inter-
est in finding effective and less toxic demethylating
agents. Zebularine is a new oral cytidine analog originally
synthesized as a cytidine deaminase inhibitor that has
shown to cause demethylation and reactivation of a
silenced and hypermethylated p16 gene in human bladder
tumor cells grown in nude mice. Zebularine was also
shown to be minimally cytotoxic in vitro and in vivo and
can be administered continuously at a lower dose to
maintain demethylation for a prolonged period, possible
only because of its low-toxicity profile; to date, there are
no results of clinical trials with this agent [60]. Within this
class of so-called "non-toxic and orally administered
agents", there is the green tea major polyphenol (-)-epi-
gallocatechin-3-gallate (EGCG) that demonstrated to be
an effective DNMT activity inhibitor at micromolar con-
centrations and that was able to demethylate and reacti-
vate expression of several tumor suppressor genes such as
p16, RAR-β2, and MGMT in cancer cell lines [61].
There is another class of so-called "old drugs" that
includes hydralazine. The demethylating activity upon
gene promoters of tumor suppressor genes of these com-
pounds was recently demonstrated. Procainamide, a non-Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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nucleoside inhibitor of DNA methyltransferases approved
for treatment of cardiac arrhythmias, can demethylate the
GSTP1 promoter, a common somatic genome change in
human prostate cancer, and reactivates expression of the
gene in vitro and in nude mice [62]. A related drug, pro-
caine, possesses the ability to demethylate and reactivate
tumor suppressor gene expression, such as the RARβ2
gene, in a breast cancer cell line, an effect accompanied by
growth-inhibitory actions [63].
Hydralazine as a demethylating agent
Clues to underscoring hydralazine's DNA demethylating
property have derived from its ability to induce a lupus-
like syndrome in connection with studies demonstrating
DNA methylation disorder participation in systemic lupus
erythrematosus (SLE).
Lupus-like syndrome induced by hydralazine
More than 80 drugs have been associated with drug-
induced lupus erythrematosus [64]; at least 39 of these are
currently in use [65]. Only two of these, procainamide
and hydralazine, are considered as high risk for induction
of the syndrome, with up to 8 and 20% frequency respec-
tively, during 1 year of therapy at currently employed
doses [64,65]. Hydralazine was introduced as an antihy-
pertensive drug in 1952, and the first case of hydralazine-
induced lupus was reported soon thereafter [66]. Preva-
lence of slow acetylators among patient populations at
Expression of the mRNA and proteins of A, ER (MDA-231);  B, RARβ (MCF-7); and C, p16 (T24) genes by RT-PCR and  Western blot Figure 2
Expression of the mRNA and proteins of A, ER (MDA-231); 
B, RARβ (MCF-7); and C, p16 (T24) genes by RT-PCR and 
Western blot. The positive control (+ctr) for A is MCF-7, for 
B is MDA-231 exposed to 5-aza-CdR/atRA, and for C is 
HeLa cells. (Reproduced with permission from the AACR. 
Ref. 83. Clin Cancer Res 2003, 9:1596–1603).
Methylation analysis of the ER, RARβ, and p16 genes Figure 1
Methylation analysis of the ER, RARβ, and p16 genes. A, G is 
undigested genomic DNA as positive control, H is HpaII, and 
M is MspI. The band in H of control lanes indicates lack of 
digestion with HpaII and, therefore, methylation of untreated 
MDA-231 cells. B and C show the analysis by methylation-
specific PCR of RARβ and p16 genes in MCF-7 and T24 cells. 
W is wild type, M is methylated primers, and U is unmethyl-
ated primers. D and E show a time course experiment of 
RARβ and p16 gene demethylation over 5 days on the MCF-
7 and T24 cells, respectively. (Reproduced with permission 
from the AACR. Ref. 83. Clin Cancer Res 2003, 9:1596–1603).Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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risk for developing lupus erythrematosus is obviously
much greater than the disease prevalence. Only 1–3% of
populations of which at least 50% are slow acetylators
develop hydralazine-induced lupus. In a study of 26
patients with hydralazine-induced lupus, 25 were slow
acetylators, with a 4:1 ratio of females to males; this dis-
crepancy may be explained by the fact that additional
genetic traits are important in predisposing individuals to
lupus [67,68].
Clinical features and laboratory manifestations of drug-
induced lupus are similar to those of lupus erythremato-
sus. Symptom onset can be slow or acute, although an
interval of 1–2 months typically occurs before diagnosis is
made. As with idiopathic lupus, the most commonly
observed abnormality is the presence of anti-nuclear anti-
bodies, and these autoantibodies usually react with chro-
matin; however, unlike in patients with lupus, anti-
chromatin antibodies rarely react with native (double-
stranded DNA. In summary, neither the clinical nor the
serologic picture are specific for drug-induced or idiopatic
lupus; hence, the key (albeit retrospective) diagnostic tool
is the observation that drug-induced lupus symptoms
usually resolve within days to weeks after discontinuing
the offending drug without introduction of anti-inflam-
matory medications [64].
Mechanisms of hydralazine-induced lupus syndrome
Early studies suggested that interaction between hydrala-
zine with thymidine and deoxycytidine was at least partly
responsible for initiating the syndrome [69], and that an
immune response to hydralazine may be important in
human hydralazine-induced SLE [70].
Additional recent studies have strongly supported that
SLE pathogenesis is strongly related with disorders in
DNA methylation, beginning with an observation by
Richardson et al. that CD8 T cells treated with 5-aza-cyti-
dine – but not with hydroxyurea, a DNA synthesis inhibi-
tor – re-expressed CD4, implying that DNA methylation
may be one of the mechanisms involved in thymocyte
maturation [71]. Subsequently, the authors showed that
the 5-azacytidine-treated cloned, CD4 IL-2- dependent
antigen-specific T cells lost the requirement for antigen
and could be activated by autologous macrophages [72].
Autoreactivity correlated with over-expression at a tran-
scriptional level of lymphocyte function-associated anti-
gen-1 (LFA-1) [73], and T cells overexpressing this
molecule become auto-reactive and caused a lupus-like
disease in syngeneic mice [74] as it did in mice injected
with syngeneic normal murine T cells treated with
demethylating drugs [75,76]. Latter, it was shown that 5-
azacytidine, procainamide, and hydralazine induce
CD11a promoter demethylation and re-expression [77].
Further, it has been demonstrated that patients with rheu-
matoid arthritis and SLE had DNA hypomethylation of T
cells [78], which correlates with decreased DNA methyl-
transferase enzyme activity and DNMT1 mRNA due to
inhibited ERK pathway signaling [79]. In addition, lym-
phocytes from patients with lupus had at least over-
expression and promoter demethylation of genes coding
for CD11a [80] and CD70, a B cell co-stimulatory mole-
cule [81]. In summary, these studies indicate that DNA
hypomethylation and deregulated expression of mole-
cules including LFA-1 and CD70 are fundamental for the
pathogenesis of both drug-induced and idiopathic human
lupus.
Analysis of methylation and product expression of the ER  gene in nude mice Figure 3
Analysis of methylation and product expression of the ER 
gene in nude mice. A shows that the tumor of control mice 
(CTR lanes) was methylated as shown by the band in the 
Lane H indicating no digestion with HpaII. The band disap-
peared with the treatment with 5-aza-CdR and hydralazine, 
which indicates gene demethylation. In PROC (procainamide) 
lanes, the band is absent in MspI but is very weak in HpaII, 
indicating that was only partially demethylated; B and D are 
the product expression by RT-PCR and Western blot. In 
both cases, the intensity of bands in procainamide is weaker, 
correlating with a partial demethylation, (C and E are the 
loading controls, GAPDH and actine respectively). G is undi-
gested genomic DNA. (Reproduced with permission from 
the AACR. Ref. 83. Clin Cancer Res 2003, 9:1596–1603).Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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Hydralazine in demethylating and reactivating tumor 
suppressor genes
These observations, unrelated to the field of DNA methyl-
ation in cancer and demonstrating that hydralazine pos-
sesses DNA demethylating activity [82], led to testing the
hypothesis that hydralazine, by virtue of its DNA methyl-
ation inhibitory activity, could restore tumor suppressor
gene re-expression by relieving hypermethylation at the
gene promoter. To that end, demethylation and re-expres-
sion of tumor suppressor genes, estrogen receptor, and
p16, RARβ, which are methylated in MDA-231, T24, and
MCF-7 cell lines, respectively, were studied. Treatment of
these cell lines with hydralazine at 10 µM for 5 days led to
gene promoter demethylation at these genes, which corre-
lated with gene re-expression at the level of RNA and pro-
tein levels (Figures 1 and 2); in addition, it was shown that
the reactivated gene product was functional. Hydrala-
zine's gene-demethylating and -reactivating effects were
also observed for the estrogen receptor gene in estrogen
receptor-negative MDA231 cell-xenographed mice treated
for 7 days with hydralazine by intraperitoneal (i.p.) route
at doses equivalent to those observed in hypertensive
patients [83] (Figure 3).
With the aim of explaining hydralazine's demethylating
effects, we assessed the structural and electronic properties
between hydralazine and methyltransferase by modeling
the most stable conformation of hydralazine and the
pocket at the active site of the enzyme. Results indicate the
existence of a high-affinity interaction between hydrala-
zine and the DNA methyltransferase. The residues Lys 162
and Arg 240 within the enzyme active site demonstrated
four interacting points with hydralazine (Figure 4) at dis-
tances between these residues and hydralazine nitrogen
Docking between the enzyme DNA methyltransferase and hydralazine showing the residues at the pocket (Lys 162 and Arg  165) that interact with the hydralazine molecule Figure 4
Docking between the enzyme DNA methyltransferase and hydralazine showing the residues at the pocket (Lys 162 and Arg 
165) that interact with the hydralazine molecule (Modified from ref. 84. Lett Drug Design Discov 2005, 2:282–286).Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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atoms not exceeding 4A°. These interactions are energeti-
cally stable, supporting that hydralazine may inhibit DNA
methyltransferase [84]. These results from modeling have
been confirmed by experiments demonstrating the ability
of hydralazine at concentrations between 10 and 20 µM to
inhibit DNA methylation in an in vitro DNA methyltrans-
ferase assay (Figure 5). It remains debatable whether or
not hydralazine directly inhibits DNA methyltransferase
enzymatic activity. In fact, Richardson's group failed to
demonstrate enzymatic inhibition in vitro with hydrala-
zine; instead, the authors reported that hydralazine
decreased RNA methyltransferase 1 and 3a expression in a
similar manner to PD98059, a mitogen-activated protein
kinase kinase (MEK) inhibitor, this suggesting that
hydralazine does not directly inhibit DNA methyltrans-
ferase enzymatic activity [85]. These discrepancies with
regard to hydralazine's precise mechanism of action as
DNA methylation inhibitor may stem from the different
DNA methyltransferase assays used. Richardson's group
employed a methyltransferase assay with a partially puri-
fied enzyme obtained from Jurkat T cell lysates assayed
upon hemimethylated double-stranded oligonucleotides
and 3H-AdoMet [85], whereas our group utilized an assay
based on lack of DNA restriction after the DNA substrate
was treated with M. SssI methylase enzyme; this latter
assay has been used recently to characterize the demethyl-
ation inhibitory activity of newer demethylating com-
pounds [86]. Nevertheless, the issue concerning this direct
inhibition by hydralazine on the enzyme needs to be fur-
ther addressed. It is remarkable, however, that our group
likewise Richardson's group, also have observed
decreased expression of DNMT1 and DNMT3a, but no
DNMT3b mRNA by RT-PCR in MCF-7 cells after treat-
ment with hydralazine (Figure 6).
A recent study from the Jones group compared the DNA-
methylating and gene-reactivating activity of 5-aza-2'-
deoxycytidine against non-nucleoside inhibitors (-)-epi-
gallocatechin-3-gallate, hydralazine, and procainamide.
These authors found that 5-aza-2-deoxycytidine is far
more effective both in its DNA methylation inhibitory
activity and in its ability to reactivate methylation-
silenced genes in cancer cells [87]; nonetheless, the
authors failed to reproduce the findings obtained by the
three independent researcher groups who reported the
effect of these non-nucleosides upon DNA methylation.
Contrariwise, in a recent report the ability of hydralazine
to demethylate and reactivate estrogen receptor gene
expression was confirmed [88].
Antitumor efficacy in pre-clinical hydralazine and valproic 
acid models
Due to the well-known synergistic effect of DNA methyla-
tion and histone deacetylase inhibitors on gene re-expres-
sion and antitumor effects, the combined effect of
hydralazine and valproic acid has been investigated in
pre-clinical models. Results demonstrate that treatment
with these drugs in combination possesses a strong
growth inhibitory effect in several cell lines tested. Never-
theless, hydralazine alone at the concentration tested had
no or small growth-inhibitory properties. With the excep-
tion of 5-aza-2'-deoxycytidine, a classical cytotoxic agent
with demethylating properties [53], the in vivo or in vitro
antiproliferative effects of other DNA demethylating
agents such as procainamide, zebularine, tea polyphenol
(-)-epigallocatechin-3-gallate, and RG108 [86] are low or
absent at DNA demethylating concentrations. Interest-
ingly, MCF-7 and SW480 were more sensitive to the com-
bination of compounds, although the difference was
In in vitro methyltransferase assay of hydralazine Figure 5
In in vitro methyltransferase assay of hydralazine. There was 
no digestion with HpaII (lanes H, with 0 and 5 µM of hydrala-
zine) indicating full methylation. Starting at 10 µM of hydrala-
zine, bands in the lanes digested with HpaII (H) are visible, 
and at 20 µM the pattern of bands in HpaII (H) and MspI (M) 
digestions is similar indicating full demethylation. (MW: 
molecular weight). The substrate DNA for the in vitro meth-
ylation assay was a 1112 bp fragment of the type I Human 
Herpes Simplex virus tymidine kinase gene which has a high 
GC content. The methylation reaction contained 1 µg of sub-
strate DNA and 10 units of M.SssI methylase (0.5 µmol/L, 
New England Biolabs, Beverly, MA) in a final volume of 30 µL. 
Hydralazine was added to final concentrations of 0, 5, 10, 15, 
and 20 µmol/L starting two hours before adding the M.SssI 
enzyme for the methylation reaction. Reactions were done at 
37°C for 2 hours. After completion, the reaction the DNA 
was purified using the rapid PCR Purification system (Ijam-
sville, MD). Then, equal volumes of extracted DNA for each 
sample were placed in two separated eppendorf tubes for 
restriction enzyme digestion (one tube with HpaII and the 
other with MspI) both from New England Biolabs. Each reac-
tion contained 10 U of the enzyme, in a final reaction volume 
of 50 µL at 37° for 3 hours. After digestion, samples were 
reduced to dryness by speedvac concentration and redis-
solved in 10 µL of ddH20 and then loaded into a 2% Tris-
borate EDTA agarose gels for electrophoresis.Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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statistically significant only in SW480 cells [89] suggesting
that the known synergistic effect on tumor suppressor
gene re-activation by a DNA demethylating agent and a
HDAC inhibitor [90] lead in some models to stronger
antitumor effects [91,92].
Data on the synergy between a DNA methylation inhibi-
tor and an HDAC inhibitor for gene re-expression led to
exploration of the effect of hydralazine plus valproic acid
on global gene expression. Microarray analysis utilizing
the Amersham CodeLink system containing 55K genes
probes demonstrated that 1,281 genes (651 up-regulated
and 630 down-regulated) were differentially expressed at
least three-fold differently from an untreated control.
Among up-regulated genes, 153 were specifically induced
by hydralazine and 178, by valproic acid; however, when
cells were exposed for 4 days to hydralazine and then for
16 h to valproic acid the number increased to 352, dem-
onstrating that these epigenomic active drugs have a syn-
ergistic effect upon gene expression [89]. Synergy between
DNA methylation inhibitor 5-aza-2'-deoxycytidine and
deacetylase inhibitor trichostatin A on gene re-expression
at a global scale is already known; it has been shown that
the percentage of up-regulated genes with 5-aza-2'-deoxy-
cytidine was 1.9, 1.1 with trichostatin A, but 10.4% with
the combination [93], indicating that reversal of two epi-
genetic factors (i.e., DNA demethylation and histone
hyperacetylation) synergizes gene re-expression [94].
Among genes up-regulated by hydralazine and valproic
acid are those coding for major histocompatibility com-
plex, class I-related and major histocompatibility com-
plex, class II, DR alpha. This class I-related antigen is a
powerful NKG2D ligand for NK cell-mediated antitumor
immunity induction, whereas the DR alpha chain is cru-
cial for antigen presentation within the context of class II
MHC [95,49,50].
Upon any stimuli, cells must orchestrate a number of
changes in gene expression, as well as in other dynamic
processes such as protein phosphorylation, protein traf-
ficking, and protein-protein interactions, to cope with
cytotoxic stress [96]. Therefore, it is vital for cells to pos-
sess intact transcription regulation machinery. On this
basis, it was hypothesized that malignant cells exposed to
Expression of DNMT1 and DNMT3a in MCF-7 cells Figure 6
Expression of DNMT1 and DNMT3a in MCF-7 cells. The expression of DNMT1 and DNMT3a mRNA is decreased in MCF-7 
cells treated with hydralazine. The lower band intensity was confirmed by densitometric (right) analysis, (control is untreated 
cells). MCF-7 cells were growth arrested for 48 hours by serum deprivation, then treated for 24 hours with hydralazine at 10 
µM and then RNA extracted for analysis. Reverse transcription was carried out as previously described [110] using random 
hexamers, superscript II reverse transcriptase (Life Technologies) and 2.5 µg of total RNA as recommended by the manufac-
turer in a total volume of 50 µL. One microliter of RT reaction was used for subsequent PCR amplification for each of the 
desired transcripts with dNTPs and Amplitaq (Applied Biosystems). Primer sequences used were as follows: DNMT1 sense 5-
gat cga att cat gcc ggc gcg tac cgc ccc ag-3 and antisense 5-atg gtg gtt tgc ctg gtg c-3. DNMT3a sense 5-ggg gac gtc cgc agc gta 
cac-3 and antisense 5-cag ggt tgg act cga gaa atc g-3. Amplification conditions were: 94 C° for 5 min 1 cycle; 94 C° 30 sec, 
(58°C for DNMT1 and 65°C for DNMT3a) annealing temperature for 1 min, and 72 C° for 30 sec, 35 cycles.Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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cytotoxic chemotherapeutic drugs would have a deranged
response and that this would perhaps compromise sur-
vival if co-treated with drugs targeting two of the main
gene-regulating processes: DNA methylation and histone
acetylation. In fact, hydralazine and valproic acid
increased the cytotoxicity of chemotherapy agents cispla-
tin, doxorubicin, and gemcitabine (Figure 7) [89]; it is
noteworthy, however, that sensitization was higher for
cisplatin and doxorubicin, as could be expected because
loosening the chromatin structure by histone acetylation
increases the efficiency of anticancer drugs that target
DNA [97]. The observed chemosensitization in vitro was
evaluated in a murine model of fibrosarcoma using nude
mice xenografted with the sarcoma cell line HT1080.
Remarkably, while tumors receiving only adriamycin re-
grew 1 week after the adriamycin final dose, animals
treated with hydralazine plus valproic acid showed no
A. Pre- (dark bars) and post-hydralazine treatment (light  bars) Figure 8
A. Pre- (dark bars) and post-hydralazine treatment (light 
bars). The bars represent the number of patients that 
showed methylation for each studied gene from each of the 
16 patients. B. Representative cases of genes (M methylated, 
U unmethylated; pre/post): M/M; M/U; U/U, M/U; MU/U; M/ 
U-M. C. Percentage of demethylation after treatment 
according to the dose. Percentage was calculated considering 
100% methylation the total number of pre-treatment methyl-
ated genes in each cohort of 4 patients (Reproduced from 
ref. 74. BMC Cancer 2005, 5:44).
HeLa cells were treated for 24 hours with panel Figure 7
HeLa cells were treated for 24 hours with panel a: cisplatin 
(cddp), panel b: adriamycin (adr) or panel c: gemcitabine 
(gem) at or close to IC50 plus hydralazine (h) and valproic 
acid (v). Afterwards medium was removed and fresh medium 
containing only hydralazine and valproic acid was added for 
additional 48 hours after which viability was measured. There 
was a significant higher cytotoxicity of the chemotherapeutic 
agent when used in combination with hydralazine plus valp-
roic acid. Cisplatin alone at 12 µM caused a reduction in via-
bility to 37% in HeLa cells which was essentially zero viability 
when cells were co-treated with hydralazine plus valproic 
acid (h-v-c). The increasing toxicity of the combination was 
also seen with adriamycin and gemcitabine. Viability was 42% 
and 45% in the chemotherapy drugs alone versus 27% and 
37% respectively when hydralazine plus valproic acid were 
added to chemotherapy drugs (h-v-c). (Reproduced from ref. 
89. Cancer Cell Int 2006,6:2).Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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tumor re-growth [89]. These results suggest that the com-
bination's antitumor efficacy was higher and that there-
fore no microscopic residual remained or alternatively,
that the treatment disabled cell proliferative capacity. This
in principle may be particularly relevant for patients with
minimal residual disease after curative attempt by surgery,
chemotherapy, and/or radiotherapy.
Clinical studies of hydralazine and valproic acid in patients 
with cancer
These pre-clinical studies were the foundation for per-
forming a phase I study to investigate whether hydrala-
zine administered by oral route at doses commonly used
for treatment of high blood pressure could demethylate
and re-activate tumor suppressor gene expression in the
tumors of patients with cervical cancer [98]. The study was
performed in 16 newly diagnosed patients with cervical
cancer with locally advanced disease receiving 50, 75, 100,
or 150 mg a day for 10 days. The treatment was well-tol-
erated and methylation analysis of the biopsies taken
prior to and after 10 days of hydralazine administration
was performed in all patients. Overall, 70% (89 of 128) of
pre-treatment samples analyzed (eight genes for each of
the 16 pre-treatment biopsies) had at least one methyl-
ated gene, and all 16 patients had at least one methylated
gene. Irrespective of the hydralazine dose administered,
post-treatment biopsies showed a gene-variable demeth-
ylation rate varying from 15% (2/13 samples) for the
MGMT gene to 67% of demethylation for the p16 gene.
Correlation between demethylation analysis and dose
level revealed the following: at 50 mg a day, 40% of meth-
ylated genes suffered demethylation; at 75 mg, this was
52%; at 100 mg, the rate was 43%, and the rate was 32%
for the 150-mg dose (Figure 8).
Regarding expression of the analyzed genes, 90% (116 of
128) of tumor samples expressed the messenger in the
pre- and post-treatment biopsies regardless of methyla-
tion status; hence, these were not informative. Notwith-
standing this, nine of 12 informative cases had the gene
re-expressed after treatment: one case at 50 mg; four cases
at 75 mg; one case at 100 mg, and three cases at 150 mg
(Figure 9). Interestingly, at the doses tested there were no
observed changes in the methylation status of imprinted
and "normally methylated" genes in the DNA of periph-
eral blood cells. Additionally, hydralazine lowered global
methylcytosine content by 1% in tumors, as evaluated by
a capillary electrophoresis method [99].
It is widely accepted that cancer development has been
associated with DNA methylation deregulation and aber-
rant histone deacetylase (HDAC) activity, which cooper-
ate for inducing aberrant gene silencing [100]. Therefore,
a number of investigation groups are currently exploring
the clinical antitumor activity of a DNA methylation
inhibitor plus a histone deacetylase inhibitor [101].
Among histone deacetylase inhibitors, the discovery that
valproic acid, which belongs to the short-chain fatty acids
category and which showed to be an effective HDAC
inhibitor [102,103], encouraged investigation of this
agent as a potential cancer therapy agent. We recently
demonstrated, within the context of a phase I study, that
Representative cases correlating methylation and re-expres- sion before and after hydralazine treatment Figure 9
Representative cases correlating methylation and re-expres-
sion before and after hydralazine treatment. A is a patient 
treated with 75 mg/day that demethylated and re-expressed 
the DAPK gene. B corresponds to a patient receiving 150 
mg/day who showed only the methylated band pre-treat-
ment, but both bands after treatment, which correlated with 
re-expression of MGMT. C is a 50 mg/day patient which 
failed to demethylate the DAPK gene and therefore lacked 
expression. D represents the distribution of informative 
cases. From the 128 genes/cases, 116 were RT-PCR positive 
regardless of the methylation status, hence were not inform-
ative. In the remaining 12 cases, nine demethylated and re-
expressed the gene. (Reproduced from ref. 74. BMC Cancer 
2005, 5:44).Journal of Translational Medicine 2006, 4:10 http://www.translational-medicine.com/content/4/1/10
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magnesium valproate when used at only slightly higher
doses than those utilized as anticonvulsant, not only pro-
duces H3 and H4 histone hyperacetylation in PBMN cells,
but also leads to hyperacetylation of H3 and H4 hyper-
acetylation and HDAC activity inhibition in primary
tumors of patients with cervical cancer [104]. These data
have led us to investigate the clinical efficacy of hydrala-
zine and magnesium valproate in a series of on-going
phase II studies.
Breast cancer exhibits a number of epigenetic alterations
that potentially can be reverted by epigenetic therapies
[105]; hence, in the first study newly diagnosed patients
with locally advanced breast carcinoma receive four
courses of neoadjuvant chemotherapy with adriamycin
and cyclophosphamide plus hydralazine and magnesium
valproate on a daily basis beginning 7 days before the first
chemotherapy cycle and continuing through the end of
chemotherapy, with pathologic response rate as the end
point. Likewise, epigenetic alterations in cervical cancer
are common [106]; hence we are performing a phase II
trial in previously untreated FIGO stage IIIB cervical can-
cer. Patients receive standard weekly cisplatin plus radia-
tion along with the combination of hydralazine and
magnesium valproate with the aim of increasing clinical
complete response rate.
On the other hand, studies have shown that DNA methyl-
ation and histone deacetylase inhibitors are able to resen-
sitize drug-resistant tumors to established treatments
[107]; hence, we are testing whether the combination of
these epigenetic agents added to chemotherapy induces
responses in common solid tumors such as breast, lung,
cervical, ovarian, head & neck, prostate, and testicular car-
cinomas. In this trial, patients with measurable disease
who exhibit non-response or tumor progression after
three courses of palliative chemotherapy initiate with
hydralazine and magnesium valproate plus the same
chemotherapy scheme. Finally, we are also testing the
clinical activity of the combination alone in myelodyspla-
sic syndrome and refractory acute leukemia, because these
tumor types are responsive to a combination of DNA
demethylating and histone deacetylase inhibitors
[108,109]. In all these trials, several parameters, including
global and gene specific DNA methylation and histone
acetylation, are being evaluated to gain insight into the
predictive tumor response value of these molecular mark-
ers.
Conclusion
Targeting DNA methylation and histone deacetylase con-
stitutes a promising antitumor treatment, which is also
denominated epigenetic therapy. The fact that the most
extensively studied nucleosides with known DNA methyl-
ation inhibitory activity, 5-azacytidine and 5-aza-2'-deox-
ycytidine, exhibit myelosuppression even when used at
low doses has spurred the search for less toxic alternatives.
Among non-nucleoside demethylating agents, hydrala-
zine is a good candidate for clinical development mainly
due to the fact that its extensive use for decades for cardi-
ovascular conditions has demonstrated its tolerability and
safety. Existing data show that this agent is able to
demethylate and re-activate tumor suppressor gene
expression in patients with cancer. Its good tolerability
also permits its use in combination with an epilepsy treat-
ment-approved histone deacetylase inhibitor. The antitu-
mor efficacy and safety of this "epigenetic therapy" are
currently being evaluated in phase II studies, along with
chemotherapy and/or radiation for a variety of malignan-
cies in different scenarios. If encouraging, results of these
trials will dictate its further testing in randomized phase
III trials.
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